Deep brain stimulation — DBS — is the most invasive neuromodulation in clinical use. Electrodes are stereotactically implanted into specific deep brain structures and connected to a pulse generator. Continuous high-frequency stimulation disrupts pathological circuit activity at the target — acting essentially as a "reversible lesion" that can be adjusted, programmed, or turned off without further surgery.
- Class
- Implanted intracranial neurostimulator
- Mechanism
- Stereotactically implanted electrodes in specific deep brain targets deliver continuous high-frequency stimulation — disrupts pathological circuit activity (acts as "reversible lesion")
- Typical dose
- Surgical implantation; pulse parameters programmed and titrated post-implantation
- FDA indications
- Parkinson's disease (subthalamic nucleus, globus pallidus internus), essential tremor (VIM thalamus), dystonia (GPi), OCD (FDA HDE — humanitarian use), epilepsy. Investigational: treatment-resistant depression (subcallosal cingulate or other targets).
- Key adverse effects
- Surgical risks (hemorrhage, infection, hardware complications), stimulation-related effects (mood changes, dysarthria, paresthesias — adjustable), battery replacement
Highly effective for movement disorders. Psychiatric uses (OCD) more limited but real. Treatment-resistant depression remains investigational despite years of research. Reversible (vs. ablative lesional procedures). Multidisciplinary team required.
Movement disorders are the established applications. Subthalamic nucleus or globus pallidus internus for Parkinson's disease — particularly effective for tremor, rigidity, bradykinesia, and motor fluctuations from long-term levodopa. VIM thalamic stimulation for essential tremor — often dramatic improvement in disabling tremor. GPi for dystonia. The motor disorders are where DBS has the largest evidence base and the most established clinical role.
Deep brain stimulation is the most invasive neuromodulation — implanted electrodes delivering targeted, adjustable stimulation to specific deep brain structures.
Mechanism note: DBS is targeted, adjustable, but invasive neuromodulation — last-line for the most refractory OCD and depression, with outcomes critically dependent on target selection and a specialized team.
Psychiatric DBS is more limited. The FDA Humanitarian Device Exemption covers DBS for severe refractory OCD — patients who have failed multiple medication trials, exposure therapy, and other options. The target is typically the anterior limb of the internal capsule or related structures. Selected centers offer this; outcomes vary; the procedure remains specialized.
DBS for treatment-resistant depression has been investigated for over a decade with mixed results. Targets include subcallosal cingulate (Area 25, originally promising in open-label studies), nucleus accumbens, and others. Initial enthusiasm was tempered by trial outcomes that didn't replicate. The role of DBS in treatment-resistant depression remains research-stage in most centers. Some patients may benefit; the protocol and patient selection remain unclear.
The reversibility distinguishes DBS from older ablative neurosurgery (cingulotomy, capsulotomy). Stimulation can be adjusted, programmed, or stopped. Side effects from over-stimulation often resolve with parameter adjustment.
- Cost
- Device implantation $50,000-100,000+ plus surgical fees and ongoing programming.
- Generic status
- Implanted device.
- Formulary typical
- Medicare and commercial cover for movement disorders (PD, ET, dystonia). OCD HDE coverage variable. TRD investigational, not covered.
- Access friction
- Specialized multidisciplinary team required. Surgical implantation. Programming visits.
Prescriber tip: For movement disorders, established standard. For severe refractory OCD, specialty centers. For TRD, research-stage only.
For severe refractory movement disorders, DBS is established standard of care at specialty centers. For severe refractory OCD, DBS is an option after other treatments have failed. For treatment-resistant depression, DBS is investigational.